Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that may help modulate neural hyperactivity and sensory processing in Visual Snow Syndrome by increasing synaptic concentrations of serotonin and norepinephrine. By enhancing neurotransmitter signaling in cortico-limbic circuits, it potentially reduces aberrant visual cortex hyperexcitability and may mitigate the persistent visual disturbances characteristic of the syndrome.